Matsuo K, Friedman E, Gejman P V, Fagin J A
Division of Endocrinology, Cedars-Sinai Medical Center, University of California School of Medicine, Los Angeles 90048.
J Clin Endocrinol Metab. 1993 Jun;76(6):1446-51. doi: 10.1210/jcem.76.6.8501149.
The development and progression of thyroid tumors are associated with phenotype-specific mutations of genes involved in growth control. Thyroid cell growth is controlled in part by the interaction of TSH with its receptor, with subsequent activation of the GTP-binding protein and its effector, adenylyl cyclase. The resulting increase in intracellular cAMP stimulates growth in thyrocytes. The TSH receptor (TSH-R) is a seven-transmembrane domain receptor. Intracellular domains of the TSH-R important for signal transduction and which may serve as targets for mutational activation have been defined. In addition, mutations at specific loci of the alpha-subunit of G-protein in human thyroid tumors have been described. We examined 92 benign and malignant neoplastic thyroid tissues for possible mutations of the intracytoplasmic domains of the TSH-R known to be involved in signal transduction and for mutations within the hot spots of Gs alpha. Screening was carried out by single strand conformation polymorphism (TSH-R) or denaturing gradient gel electrophoresis (Gs alpha) of polymerase chain reaction-amplified tumor DNA. No mutations were observed in the cytoplasmic domains of the TSH-R, except for a neutral base substitution in codon 460 (GCG [Ala]-->GCA [Ala]) in 3 tumors, which was also present in constitutional DNA from the affected individuals. A heterozygous mutation of codon 201 of Gs alpha (GGT [Arg]-CAT [His]) was observed in a nodule from an adenomatous goiter. In addition, a codon 227 mutation (CAG [Glu]-CAT [His]) was identified in a follicular adenoma. We conclude that mutational activation of the intracytoplasmatic domains of the TSH-R is not a significant mechanism of thyroid tumorigenesis, whereas putative activating mutations within exons 8 and 9 of Gs alpha occur infrequently in some benign follicular tumors.
甲状腺肿瘤的发生和进展与生长控制相关基因的表型特异性突变有关。甲状腺细胞的生长部分受促甲状腺激素(TSH)与其受体相互作用的控制,随后GTP结合蛋白及其效应物腺苷酸环化酶被激活。细胞内cAMP的增加刺激甲状腺细胞生长。TSH受体(TSH-R)是一种七跨膜结构域受体。已经确定了TSH-R的胞内结构域对信号转导很重要,并且可能作为突变激活的靶点。此外,还描述了人类甲状腺肿瘤中G蛋白α亚基特定位点的突变。我们检测了92例良性和恶性甲状腺肿瘤组织,以寻找已知参与信号转导的TSH-R胞质结构域的可能突变以及Gsα热点区域内的突变。通过对聚合酶链反应扩增的肿瘤DNA进行单链构象多态性分析(TSH-R)或变性梯度凝胶电泳(Gsα)进行筛查。在TSH-R的胞质结构域中未观察到突变,除了3例肿瘤中密码子460(GCG [Ala]→GCA [Ala])的中性碱基替换,该替换也存在于受影响个体的基因组DNA中。在一例腺瘤性甲状腺肿结节中观察到Gsα密码子201的杂合突变(GGT [Arg]→CAT [His])。此外,在一例滤泡性腺瘤中鉴定出密码子227突变(CAG [Glu]→CAT [His])。我们得出结论,TSH-R胞质结构域的突变激活不是甲状腺肿瘤发生的重要机制,而Gsα第8和9外显子内的推定激活突变在一些良性滤泡性肿瘤中很少发生。